Galida Uses, Dosage, Side Effects and more
Galida is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Galida is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.
Treatment with tesaglitazar lowered fasting plasma glucose, improved glucose tolerance, substantially reduced fasting and postload insulin levels, and markedly lowered fasting TG and improved lipid tolerance.
| Trade Name | Galida |
| Generic | Tesaglitazar |
| Tesaglitazar Other Names | Tesaglitazar |
| Type | |
| Formula | C20H24O7S |
| Weight | Average: 408.465 Monoisotopic: 408.124273812 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in diabetes mellitus type 2.
